Logo image of AEON

AEON BIOPHARMA INC (AEON) Stock Fundamental Analysis

NYSEARCA:AEON - American Stock Exchange - US00791X1000 - Common Stock

0.154  -0.02 (-9.89%)

After market: 0.1381 -0.02 (-10.32%)

Fundamental Rating

1

AEON gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. AEON may be in some trouble as it scores bad on both profitability and health. AEON has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AEON had negative earnings in the past year.
In the past year AEON has reported a negative cash flow from operations.
In multiple years AEON reported negative net income over the last 5 years.
In the past 5 years AEON always reported negative operating cash flow.
AEON Yearly Net Income VS EBIT VS OCF VS FCFAEON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

1.2 Ratios

Industry RankSector Rank
ROA -116.07%
ROE N/A
ROIC N/A
ROA(3y)-176.64%
ROA(5y)-75.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AEON Yearly ROA, ROE, ROICAEON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 200 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AEON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AEON Yearly Profit, Operating, Gross MarginsAEON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 2K 4K

More info and screens

0

2. Health

2.1 Basic Checks

AEON has more shares outstanding than it did 1 year ago.
There is no outstanding debt for AEON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AEON Yearly Shares OutstandingAEON Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
AEON Yearly Total Debt VS Total AssetsAEON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

AEON has an Altman-Z score of -87.60. This is a bad value and indicates that AEON is not financially healthy and even has some risk of bankruptcy.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -87.6
ROIC/WACCN/A
WACCN/A
AEON Yearly LT Debt VS Equity VS FCFAEON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 0.48 indicates that AEON may have some problems paying its short term obligations.
A Quick Ratio of 0.48 indicates that AEON may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.48
Quick Ratio 0.48
AEON Yearly Current Assets VS Current LiabilitesAEON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for AEON have decreased strongly by -409.61% in the last year.
EPS 1Y (TTM)-409.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AEON will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.04% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y161.54%
EPS Next 2Y18.75%
EPS Next 3Y11.91%
EPS Next 5Y17.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AEON Yearly Revenue VS EstimatesAEON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
AEON Yearly EPS VS EstimatesAEON Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AEON. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 0.21, which indicates a rather cheap valuation of AEON.
The average S&P500 Price/Forward Earnings ratio is at 24.11. AEON is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 0.21
AEON Price Earnings VS Forward Price EarningsAEON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.03
AEON Per share dataAEON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.75%
EPS Next 3Y11.91%

More info and screens

0

5. Dividend

5.1 Amount

AEON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AEON BIOPHARMA INC

NYSEARCA:AEON (1/17/2025, 8:04:02 PM)

After market: 0.1381 -0.02 (-10.32%)

0.154

-0.02 (-9.89%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change0.04%
Ins OwnersN/A
Ins Owner Change6.87%
Market Cap5.72M
Analysts82.86
Price Target5.1 (3211.69%)
Short Float %0.56%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)119.35%
Min EPS beat(2)-74.02%
Max EPS beat(2)312.73%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.21
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 0.03
EPS(TTM)-0.56
EYN/A
EPS(NY)0.73
Fwd EY476.88%
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0
BVpS-4.12
TBVpS-4.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -116.07%
ROE N/A
ROCE -349.13%
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-176.64%
ROA(5y)-75.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.48
Quick Ratio 0.48
Altman-Z -87.6
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-409.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y161.54%
EPS Next 2Y18.75%
EPS Next 3Y11.91%
EPS Next 5Y17.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y750.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-4773.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4773.09%
OCF growth 3YN/A
OCF growth 5YN/A